Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine for Chronic Post-Traumatic Headache
NCT00219869Phase 4Unknown
- Start
- Jul 2005
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of galantamine in chronic post-traumatic headache (CPTHA) and cognitive impairment. Primary endpoint: Number of pain free days at 3 months. Status: unknown.
02
Drugs
galantamine
03
Conditions
chronic post-traumatic headache (CPTHA)cognitive impairment
Beyond the preview
Go deeper on NCT00219869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00219869.